---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-23-000038"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T13:58:31.748848+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xencor sells Ultomiris and Monjuvi royalty rights to OMERS for $215M upfront

## Summary
- OMERS pays $192.5M for Ultomiris royalties from July 2023 through end-2025, then annual caps starting in 2026.
- OMERS pays $22.5M for Monjuvi royalties until OMERS receives 1.3x purchase price; excess reverts to Xencor.
- Xencor eligible for an additional $12M milestone from OMERS if certain Ultomiris sales targets met.
- Xencor retains economic upside above annual royalty caps ($35M from 2026-2028, $12M from 2029 onward).
- Cash proceeds strengthen balance sheet to fund internal pipeline programs.

## SEC filing metadata
- accession: 0001326732-23-000038
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000038/0001326732-23-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000038/xncr-20231103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-23-000038
- JSON: https://secwatch.observer/filing/0001326732-23-000038.json
- Plain text: https://secwatch.observer/filing/0001326732-23-000038.txt

## Key facts
- Material Agreements
  Xencor Inc entered into Ultomiris Agreement with OCM Life Sciences Portfolio LP valued at upfront payment of $192.5 million (effective 2023-11-03).
  - Action: entry
  - Counterparty: OCM Life Sciences Portfolio LP
  - Value: upfront payment of $192.5 million
  - Effective: 2023-11-03
  source text: On November 3, 2023, Xencor, Inc. (the “Company”) and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans (“OMERS”) entered into a royalty purchase agreement (the “Ultomiris Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000038/0001326732-23-000038-index.htm
- Material Agreements
  Xencor Inc entered into Monjuvi Agreement with OCM Life Sciences Portfolio LP valued at upfront payment of $22.5 million (effective 2023-11-03).
  - Action: entry
  - Counterparty: OCM Life Sciences Portfolio LP
  - Value: upfront payment of $22.5 million
  - Effective: 2023-11-03
  source text: (the “Company”) and OCM Life Sciences Portfolio LP, an investment vehicle of OMERS, one of Canada’s largest defined benefit pension plans (“OMERS”) entered into a royalty purchase agreement (the “Ultomiris Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000038/0001326732-23-000038-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.